_edited.png)
Wockhardt Ltd
Soars 11.5% to a Record High - Has a 13-Year Breakout Finally Found Its Trigger ?
Wockhardt shares surged 11.5% to an all-time high after the company received regulatory approval for its newly developed antibiotic, Zaynich. The breakthrough drug, aimed at treating complex bacterial infections, has reignited investor interest, helping the stock break out of a 13-year consolidation phase and emerge as one of the top-performing stocks in the Nifty 500.
The primary catalyst behind Wockhardt's sharp rally was the approval from the Central Drugs Standard Control Organisation (CDSCO) to market Zaynich in India. The antibiotic is a combination of Zidebactam and Cefepime and is approved for treating complicated urinary tract infections (cUTI), including kidney infections and cases accompanied by Gram-negative bacteremia—a serious bloodstream infection. The approval marks a significant milestone for Wockhardt's innovation-driven pharmaceutical business.
Beyond the immediate approval, investors are focusing on the commercial potential of Zaynich. While the domestic market opportunity is estimated at ₹150–200 crore annually, the global addressable market is estimated at around $5 billion. Given the increasing global challenge of antimicrobial resistance, successful commercialization of the drug could open a meaningful long-term growth avenue for the company.
The rally is particularly noteworthy because it has pushed Wockhardt out of a consolidation range that lasted more than a decade. The stock touched a record high of ₹1,975.50 and has gained around 36% during the month. Market participants view this breakout as a strong technical signal, supported by rising volumes and improving sentiment around the company's pharmaceutical pipeline.
Technical indicators continue to reflect strong buying interest. The stock is trading above all major moving averages, ranging from the 5-day to the 200-day average, indicating a sustained uptrend. Its Relative Strength Index (RSI) stands above 70, suggesting strong momentum, although it also signals that the stock may be entering overbought territory in the near term.
Wockhardt's rally is being driven by more than just a regulatory approval. Investors are increasingly assigning value to the company's research-driven business model, innovative anti-infective pipeline, and the significant global market opportunity for Zaynich. The combination of a major product approval, long-awaited technical breakout, and strong growth potential has turned Wockhardt into one of the most closely watched pharmaceutical stocks in the market.
Latest News
Angel One Client Base Grows But Trading Activity And Market Share Decline
Angel One reported strong client and funding book growth in August, but trading activity weakened with lower order volumes, average daily orders and notional turnover. The brokerage also recorded a decline in retail turnover market share across equity, futures and options and commodities.
4:45 pm
4 September 2026
UltraTech Entry Into Wires And Cables Triggers Selling In Rival Stocks
Shares of major wires and cables companies declined sharply on September 4 after UltraTech Cement launched its Ultravolt business, raising concerns over increased competition in the segment. KEI Industries, Polycab India and RR Kabel were among the key stocks under pressure as UltraTech outlined plans to invest Rs 1,800 crore and rapidly expand its presence across India.
3:38 pm
4 September 2026
HAL Gains As GE Aerospace Delivers Three F404 Engines For Tejas Mk1A
Shares of Hindustan Aeronautics gained in early trade after GE Aerospace delivered three F404-IN20 engines to HAL in August for the LCA Tejas Mk1A programme. The latest shipment takes cumulative engine deliveries to 10 and could support HALs production ramp up as engine availability has been a key bottleneck for aircraft deliveries.
3:00 pm
4 September 2026
Gland Pharma Sees 45 Percent Stake Change Hands In Block Deal
A 4.5 percent stake in Gland Pharma worth around Rs 2,121 crore changed hands through a block deal on Friday, a day after reports indicated that promoter Fosun Pharma was looking to sell up to a 5 percent stake. The transaction involved 75 lakh shares at an average price of around Rs 2,828 per share.
2:55 pm
4 September 2026
Banking Stocks Rally As Strong FCNRB Inflows Boost Liquidity And Rupee
Banking stocks advanced sharply after the Reserve Bank of Indias overseas capital raising measures attracted a stronger than expected $136.38 billion in foreign currency inflows. The surge in FCNRB deposits and other foreign currency borrowings improved banking system liquidity and strengthened the rupee, supporting broad based gains across private and PSU banks.